Company intelligence / Profile preview

AgeneTech

Baltimore, Maryland, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

AgeneBio is a clinical-stage biotechnology company focused on developing innovative therapeutics for neurological and psychiatric diseases characterized by hippocampal overactivity. The company's lead program, AGB101, is a once-a-day low-dose formulation of levetiracetam currently in Phase 3 clinical trials for the treatment of mild cognitive impairment due to Alzheimer's disease. AgeneBio is also advancing a discovery-stage pipeline of GABA-A alpha 5 positive allosteric modulators intended to restore hippocampal inhibitory-excitatory balance. By targeting the underlying circuitry of memory loss, the company aims to delay the progression of Alzheimer's dementia and address other CNS disorders.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Johns Hopkins University

Beyond the preview

Go deeper on AgeneTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AgeneTech.

Explore the full profile